A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 44-53

  Schlumberger, Martin ^a   Jarzab, Barbara ^b   Cabanillas, Maria E ^c   Robinson, Bruce ^d   Pacini, Furio ^e   Ball, Douglas W ^f   McCaffrey, Judith ^g   Newbold, Kate ^h   Allison, Roger ⁱ   Martins, Renato G ^j   Licitra, Lisa F ^k   Shah, Manisha H ^l   Bodenner, Donald ^m   Elisei, Rossella ⁿ   Burmeister, Lynn ^o   Funahashi, Yasuhiro ^p   Ren, Min ^p   O'Brien, James P ^p   Sherman, Steven I ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k NATIONAL CANCER INSTITUTE   (Italy)

^l THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

ⁿ UNIVERSITY OF PISA   (Italy)

^o UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^p EISAI INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; INTERLEUKIN 8; LENVATINIB; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CONSTIPATION; COUGHING; DEATH; DECREASED APPETITE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; GLOSSODYNIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MEDULLARY THYROID CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; ONCOGENE RET; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; STOMATITIS; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; AGED; BLOOD; CANCER STAGING; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIAL; DISEASE COURSE; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RETREATMENT; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, NEUROENDOCRINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; RETREATMENT; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954523871     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1127     Document Type: Article

References (37)

1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
2. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
3. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
4. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88: 2070-5.
5. Sippel RS, Kunnimalaiyaan M, Chen H. Currentmanagement ofmedullary thyroid cancer. Oncologist 2008;13:539-47.
6. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012; 14:97-104.
7. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007;58:253-65.
8. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
9. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 2010;163:301-8.
10. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682-7.
11. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011;96:E863-8.
12. Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, et al. Activation of the mTOR pathway in primarymedullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 2012;18:3532-40.
13. Blaugrund JE, Johns MM Jr, Eby YJ, Ball DW, Baylin SB, Hruban RH, et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895-7.
14. Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin E, Leboulleux S. Kinase inhibitors for advancedmedullary thyroid carcinoma. Clinics (Sao Paulo) 2012;67:125-9.
15. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155: 1967-76.
16. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010;20:863-71.
17. Rodríguez-Antona C, Pallares J, Montero-Conde C, Inglada-Pérez L, Castelblanco E, Landa I, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010;17:7-16.
18. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41.
19. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46.
20. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-71.
21. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multikinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-65.
22. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340:97-103.
23. Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18.
24. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. NEngl J Med 2015;372:621-30.
25. Matsui J, Minoshima Y, Tsuruoka A, Funahashi Y. Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition [abstract]. Cancer Res 2010;70: Abstract 3614.
26. Glen H, Mason S, Patel H, Macleod K, Brunton VG. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309.
27. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106:1598-604.
28. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014: 638747.
29. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 2015;121:2749-56.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28: 767-72.
32. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
33. European Medicines Agency. Committee for medicinal products for human use (CHMP). Caprelsa (vandetanib). Procedure no. EMEA/H/C/002315//0000.2011[cited2015May 11]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002315/WC500123603.pdf.
34. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6.
35. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71.
36. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100.
37. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 2014;8:696-706.